Dolutegravir 50 mg twice daily + Dolutegravir placebo twice daily
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HIV Infections
Conditions
HIV Infections
Trial Timeline
Apr 18, 2012 → Dec 16, 2013
NCT ID
NCT01568892About Dolutegravir 50 mg twice daily + Dolutegravir placebo twice daily
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice daily is a phase 3 stage product being developed by Shionogi for HIV Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01568892. Target conditions include HIV Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01568892 | Phase 3 | Completed |
Competing Products
20 competing products in HIV Infections